ArticleInternational journal of pharmaceutics: X2026
Unlocking the potential of alkaline polymethacrylates via ionic crosslinking in amorphous solid dispersions.
Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From prediction to performance:International journal of pharmaceutics: X · 2026Article
- Tailored Drug Release with Improved Solubility via Spray Drying and Functional Ready-to-Fill Capsules.Pharmaceutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amorphous solid dispersions (ASDs) are a well-established strategy to enhance the oral bioavailability of poorly water-soluble drugs; however, their broader application remains limited by drug-polymer compatibility and pronounced pH-dependent performance. In this study, alkaline polymethacrylates (Eudragit® E) are investigated as versatile carrier systems for ASDs targeting poorly water-soluble BCS Class II drugs, using acid-modified formulations to enable functionality under physiological conditions. ASDs were prepared by hot-melt extrusion (HME) and vacuum compression molding (VCM) to assess process robustness, drug-polymer miscibility, thermal behavior, and dissolution performance. Solid-state characterization confirmed complete amorphization and stable glass formation across multiple drug loadings. The presence of organic acids induced controlled protonation of the polymer, giving rise to an ionically crosslinked polymer-acid network with distinct thermal signatures and enhanced structural stability. Dissolution studies demonstrated rapid generation and prolonged maintenance of supersaturation in phosphate buffer at pH 6.8, significantly exceeding the thermodynamic solubility of the investigated drugs. Supersaturation behavior correlated strongly with the calculated degree of polymer protonation rather than with acid content alone, indicating that protonation-controlled polymer solubilization governs dissolution performance. Long-term stability testing further demonstrated preserved amorphous structure and consistent dissolution behavior under both standard and accelerated storage conditions. Overall, this work establishes acid-modified alkaline polymethacrylates as a broadly applicable platform for ASD formulation. By decoupling solubility enhancement from specific drug chemistries through polymer-driven ionic crosslinking, this approach expands the design space of ASDs and enables the rational development of stable, high-performance formulations for poorly water-soluble drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.